![PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast artwork](https://is3-ssl.mzstatic.com/image/thumb/Podcasts113/v4/12/35/a6/1235a6f7-320a-db51-94c0-bbcbcd171dd6/mza_3933038130939089111.jpg/100x100bb.jpg)
Matthew R. Weir, MD - Addressing the Disease Burden Associated With Anemia of Chronic Kidney Disease: Expert Insight on the Clinical Potential of HIF-PH Inhibitors
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
English - January 08, 2020 23:00 - 41 minutes - ★★★ - 4 ratingsScience cme medical education cme credits peerview insession inreview endocrinology diabetes cne Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Go online to PeerView.com/DUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the management of anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia because of CKD, Compare current and emerging treatments for CKD-associated anemia in terms of their mechanisms of action, efficacy, and safety, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor